Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Pancreatic Neoplasms × Valacyclovir × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Prostatic Neoplasms 3 Glioblastoma 3 Epstein-Barr Virus Infections 3 Lung Neoplasms 2 Leukemia 2 Glioma 2 Cytomegalovirus Infections 2 Astrocytoma 2 Waldenstrom Macroglobulinemia 1 Uveal Melanoma 1 Triple Negative Breast Neoplasms 1 Stomatitis 1 Pleural Effusion, Malignant 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Mesothelioma 1 Melanoma 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Infectious Mononucleosis 1 Head and Neck Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Brain Neoplasms 1 Adenocarcinoma 1

Interventions

Gemcitabine 574 130-nm albumin-bound paclitaxel 163 Fluorouracil 157 Oxaliplatin 141 Albumin-Bound Paclitaxel 126 Leucovorin 109 Capecitabine 109 Irinotecan 93 Radiotherapy 82 Taxes 70 pembrolizumab 69 Cisplatin 65 Erlotinib Hydrochloride 60 Radiosurgery 58 Nivolumab 45 Bevacizumab 45 Cyclophosphamide 43 Magnetic Resonance Spectroscopy 39 Drug Therapy 38 Docetaxel 36 Cetuximab 35 folfirinox 32 S 1 (combination) 31 irinotecan sucrosofate 30 Specimen Handling 30 Paclitaxel 26 Radiation 24 Biopsy 24 Surgical Procedures, Operative 21 fludarabine 20

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00638612 2023-08-25

PaTK01

Candel Therapeutics, Inc.

Phase 1 Completed

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡